Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.46 |
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 6/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4943678 | 0.85 | CYP1A1 (0.64) | CYP1A1CYP1B1SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL22749443 | 0.83 | SMN1; SMN2 (0.64) | CYP1A1CYP1B1SMN1; SMN2TP53ALDH1A1 | |
| Bromide SCHEMBL4940376 | 0.83 | SLC2A1 (0.52) | CYP1A1CYP1B1SMN1; SMN2TP53ALDH1A1 | |
| Bromide SCHEMBL22749631 | 0.82 | SMN1; SMN2 (0.57) | CYP1A1CYP1B1SMN1; SMN2TP53ALDH1A1 | |
| Bromide SCHEMBL22749619 | 0.81 | SMN1; SMN2 (0.61) | CYP1A1CYP1B1SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL22761785 | 0.80 | SMN1; SMN2 (0.55) | CYP1A1CYP1B1SMN1; SMN2TP53ALDH1A1 | |
| Bromide SCHEMBL22749451 | 0.79 | SLC2A1 (0.51) | CYP1A1CYP1B1SMN1; SMN2TP53ALDH1A1 | |
| Bromide SCHEMBL4937762 | 0.78 | CYP1A1 (0.45) | CYP1A1CYP1B1SMN1; SMN2TP53ALDH1A1 | |
| Bromide SCHEMBL22749630 | 0.78 | SMN1; SMN2 (0.52) | CYP1A1CYP1B1SMN1; SMN2TP53ALDH1A1 | |
| Bromide SCHEMBL22749450 | 0.76 | HTT (0.47) | CYP1A1CYP1B1SMN1; SMN2TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319032-A1 | TETRAHYDROBENZOTHIAZOLE ANALOGUES AS NEUROPROTECTIVE AGENTS | GREIG NIGEL H | 2008-12-25 | — | — | US | disclosed |
| US-20040067991-A1 | Tetrahydrobenzothiazole analogues as neuroprotective agents | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE | 2004-04-08 | — | — | US | disclosed |
| EP-1303502-A2 | TETRAHYDROBENZOTHIAZOLE ANALOGUES AS NEUROPROTECTIVE AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002004409-A2 | TETRAHYDROBENZOTHIAZOLE ANALOGUES AS NEUROPROTECTIVE AGENTS | US GOV HEALTH & HUMAN SERV (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067991-A1 | Tetrahydrobenzothiazole analogues as neuroprotective agents | BAX, BAD, BCL2 | SIGMAR1 933/4885CYP1A1 2492/4885CYP1B1 1165/4885 |
| US-20080319032-A1 | TETRAHYDROBENZOTHIAZOLE ANALOGUES AS NEUROPROTECTIVE AGENTS | BAX, BAD, BCL2 | SIGMAR1 933/4885CYP1A1 2492/4885CYP1B1 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.